An Open-Label, Phase 4 Study to Evaluate the Efficacy and Safety of Triple Combination Therapy with Vedolizumab IV, Adalimumab SC, and Oral Methotrexate in Early Treatment of Subjects with Crohn’s Disease Stratified at Higher Risk for Developing Complications (Takeda Vedolizumab-4006).
This is a phase 4 research study for patients with newly diagnosed with Crohn’s disease within the last 24 months, aged 18-80 years old. Participants will remain on the study and continue to receive the study investigational medication and until the study is completed unless they are Early Discontinued or voluntarily end participation. It is estimated that patients will participate for a minimum of approximately 2 years. During this time, participants will be evaluated by the study team every 2-4 weeks for up to 128 weeks.
For more information or eligibility criteria, call our Research Hotline number at 612-870-5599, OR input the following information and we will follow up with you to discuss your interest: